JI-101

DRUG2 trials

Sponsors

Jubilant Innovation Ltd., University of Utah

Conditions

Advanced Solid TumorsCancerColon CancerNeuroendocrineOvarian Cancer

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors

CompletedNCT00842335

Jubilant Innovation Ltd.Advanced Solid Tumors

Start: 2009-02-28End: 2012-01-31Updated: 2013-06-24

Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

TerminatedNCT01149434

University of UtahCancer, Colon Cancer, Neuroendocrine +1

Start: 2010-09-30End: 2012-08-31Updated: 2014-10-06